

2021-2022

American Heart Association

Funding from Pharmaceutical and Biotech Companies and Device Manufacturers

We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association’s finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau’s Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations and estates as well as revenue from the sale of mission-aligned products and services, such as CPR training, and investment earnings.

Financial support from corporations helps the association’s programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association’s corporate relations policies and are approved by a committee of national volunteers and executive staff.

Total corporate funding is comprised of unrestricted gifts, special event and program sponsorships and fees from program-related services. Corporate funding represents approximately 21.7 percent of the AHA’s \$880 million total revenue.

Funding that the American Heart Association receives from pharmaceutical and biotech companies and device manufacturers is included within total corporate funding and represents approximately 3.8 percent of the association’s total revenue.

The revenue figures below include the total amount of funds earned or committed to the American Heart Association during fiscal year 2021-2022, noting that, in some cases, the funds will be received in future years. The chart provides funds from pharmaceutical and biotech companies and device manufacturers in proportion to all sources of revenue.



Following is a schedule of corporate funding provided to the American Heart Association from pharmaceutical and biotech companies and medical device manufacturers during fiscal year 2021-2022. The schedule reflects cash received during fiscal year 2021-2022 and revenue committed to the American Heart Association that will be received in future years.

2021-2022 Corporate Funding Received from Pharmaceutical and Biotech Companies and Device Manufacturers		
Corporation	Total Cash Received During 2021-2022 on Prior and Current Year Commitments (1)	2021-2022 Commitments Receivable in the Future
Abbott	171,500	200,000
Alexion Pharmaceuticals Inc.	1,355,000	-
Alnylam Pharmaceuticals	375,000	-
Amarin Pharma, Inc.	52,500	-
Amgen	1,994,000	1,610,000
AstraZeneca Pharmaceuticals LP	473,000	-
AtriCure, Inc	90,000	265,000
Bayer Healthcare Pharmaceuticals Inc	1,608,973	853,333
Boehringer Ingelheim Pharmaceuticals	2,502,500	-
Boston Scientific	108,500	120,000
Bristol Myers Squibb	2,808,650	-
Cerenovus	65,000	-
Chiesi USA, Inc.	93,000	-
CSL Behring	70,000	-
Cytokinetics, Incorporated	415,500	-
Edwards Lifesciences	3,172,500	-
Esperion Therapeutics	273,500	-
FUJIFILM Diosynth Biotechnologies	15,000	65,000
GlaxoSmithKline	82,000	-
Ipsen Biopharmaceuticals, Inc	150,000	300,000
Janssen Pharmaceuticals	906,116	-
Jazz Pharmaceuticals	50,000	-
Johnson & Johnson	1,178,605	30,000
Kaneka North America LLC	171,416	-
Kiniksa Pharmaceuticals	523,800	-
Laerdal	910,000	-
Medtronic	2,011,813	950,000
Merck Sharp & Dohme LLC	810,000	250,000
MicroVention	122,135	15,000
Novartis	9,100,543	4,806,730
Novo Nordisk Inc.	2,182,505	3,750,000
Pfizer	1,656,275	1,975,000
Phlow	50,000	100,000
Reckitt/RB Health	250,000	-
Regeneron Pharmaceuticals	77,500	-
Roche Diagnostics	-	85,000
Sage Therapeutics	300,000	-
Sanofi	1,756,211	100,000
Schiller Americas, Inc	115,500	-
Verily (Google Life Science LLC)	7,095,913	-
Totals	45,144,458	15,475,063

NOTE: (1) Includes all cash received from corporate contributions and earned revenue greater than \$50,000. Revenue related to the cash receipts was recorded within AHA's financial statements over the periods from fiscal year 2015-2016 through fiscal year 2021-2022.